![David Lacey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Lacey
Directeur/Bestuurslid bij
NURIX THERAPEUTICS, INC.
Vermogen: 3 M $ op 31-07-2026
Profiel
Dr. David L.
Lacey, MD, is a Venture Partner at Ysios Capital Partners SGEIC SA, an Independent Director at Arcus Biosciences, Inc., an Independent Director at Atreca, Inc., an Independent Director at Nurix Therapeutics, Inc. and an Independent Non-Executive Director at Inbiomotion SL.
He is on the Board of Directors at Arcus Biosciences, Inc., Atreca, Inc., Nurix Therapeutics, Inc. and Inbiomotion SL.
Dr. Lacey was previously employed as an Independent Director by Unity Biotechnology, Inc., an Independent Non-Executive Director by argenx SE, a Senior Vice President-Discovery Research by Amgen, Inc., an Assistant Professor by Jewish Hospital, and an Associate by The University of Colorado.
He also served on the board at Rainier Therapeutics, Inc. He received his undergraduate degree from the University of Colorado Denver and a doctorate degree from The University of Colorado School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 11-06-2026 | 76.652 ( 0,06% ) | 2 M $ | 31-07-2026 | |
| 15-05-2026 | 33.333 ( 0,03% ) | 773 659 $ | 31-07-2026 |
Actieve functies van David Lacey
| Bedrijven | Functie | Begin |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Directeur/Bestuurslid | 20-05-2024 |
| ATRECA, INC. | Directeur/Bestuurslid | 31-05-2016 |
| ARCUS BIOSCIENCES, INC. | Directeur/Bestuurslid | 21-05-2020 |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Designs and develops diagnostic assays | Directeur/Bestuurslid | 01-12-2012 |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital invests in companies located across the globe. The firm targets companies operating in the fields of the biotechnology sector. It provides financing for early and growth stage capital requirements. | Private Equity Investor | 01-06-2020 |
Eerdere bekende functies van David Lacey
| Bedrijven | Functie | Einde |
|---|---|---|
| ARGENX SE | Directeur/Bestuurslid | 11-05-2021 |
| UNITY BIOTECHNOLOGY, INC. | Directeur/Bestuurslid | 14-12-2020 |
| AMGEN INC. | Corporate Officer/Principal | 01-01-2011 |
The University of Colorado
 The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| ░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Opleiding van David Lacey
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
92
Eerstegraads connecties
13
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 13 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Atreca, Inc.
 Atreca, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops novel antibody-based immune therapeutics to treat a range of solid tumor cancers | Health Technology |
Nurix Therapeutics, Inc.
 Nurix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a a clinical stage biopharmaceutical company that discovers, develops and commercializes oral, small molecule therapies for the treatment of cancer & immune disorders | Health Technology |
The University of Colorado
The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital invests in companies located across the globe. The firm targets companies operating in the fields of the biotechnology sector. It provides financing for early and growth stage capital requirements. | Finance |
argenx SE
 argenx SE BiotechnologyHealth Technology Develops therapies and medicines for the treatment of autoimmune diseases | Health Technology |
Jewish Hospital
 Jewish Hospital Hospital/Nursing ManagementHealth Services Operates a hospital | Health Services |
Inbiomotion SL
Inbiomotion SL Medical SpecialtiesHealth Technology Designs and develops diagnostic assays | Health Technology |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer | Health Technology |
University of Colorado Denver
 University of Colorado Denver Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Colorado School of Medicine
 The University of Colorado School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Unity Biotechnology, Inc.
 Unity Biotechnology, Inc. BiotechnologyHealth Technology Engages in the research and development of therapeutics to extend the human healthspan | Health Technology |
Arcus Biosciences, Inc.
 Arcus Biosciences, Inc. BiotechnologyHealth Technology Develops and commercializes novel therapies for the treatment of lung & gastrointestinal cancers | Health Technology |
